Lunaphore to host The Spatial Biology Week™ 2022 virtual meeting

LAUSANNE, Switzerland – September 6, 2022 – 5:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the second edition of The Spatial Biology Week™, taking place virtually October 3-7, 2022. After last year’s significant participation with more than 500 worldwide registrants, the 1-week online meeting returns to bring experts from industry and academia together to discuss innovations and insights in the spatial biology field. Registration is free and open to the scientific community.

The events and activities planned around The Spatial Biology Week™ will explore how new, cutting-edge technology solutions in spatial biology can accelerate research and help scientists and clinicians gain a profound knowledge of the underlying pathophysiological states of diseases. These innovative approaches can potentially develop the next generation of personalized diagnostics and therapies by lowering the barriers that currently prevent the broad adoption of spatial biology.

“Aligned with our overarching goal to accelerate spatial biology adoption in labs throughout the world, it is our mission and responsibility to foster collaboration within the scientific community and bring awareness to the latest research and innovation leading the spatial biology revolution”, said Ata Tuna Ciftlik, Ph.D., Chief Executive Officer of Lunaphore.

Lunaphore’s mission to address the complexity of spatial biology by uniting the scientific community and empowering researchers with wide-ranging knowledge has been welcomed by top-notch scientists and innovators of the field. Confirmed speakers¹ include:

 

Jared K. Burks, Ph.D. – Co-Director, Flow Cytometry & Cell Imaging Core Facility and Professor, The University of Texas MD Anderson Cancer Center (USA)

Carlo Bifulco, MD – Medical Director of Oncological Molecular Pathology and Pathology Informatics at Providence, Director of Translational Molecular Pathology at the Earle A. Chiles Research Institute (USA)

Joe Yeong, MBBS Ph.D. – Group Leader Institute of Molecular and Cell Biology, IMCB, A*STAR, Singapore General Hospital (Singapore)

Denis Schapiro, Ph.D. – Group Leader, Heidelberg University Hospital (Germany)

Michael Surace, Ph.D. – Director, AstraZenenca (USA)

Ghislaine Lioux, Ph.D. – Senior Application Scientist EMEA, Indica Labs (USA)

Kelly Hunter. MSc – Chief Scientific Officer, ProPath (UK)

Charlotte Stadler, Ph.D. – Co-Director Spatial and Single Cell Biology Platform, Head of Spatial Proteomics, SciLifeLab (Sweden)

Alexander Klimowicz, Ph.D. – Senior Principal Scientist Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals (USA)

Matthew Pugh, Ph.D. – MRC Clinical Research Training Fellow, University of Birmingham (UK)

 

During the meeting, speakers from first-class industry and academic research institutions will present data across various disciplines, and Key Opinion Leaders will lead roundtable discussions to highlight the benefit and flexibility of spatial biology in fundamental to translational and clinical research settings. The engaging sessions will feature talks on immuno-oncology, pathology, immunology, and virology, among other fields, as well as cover biopharma approaches to spatial biology technologies and future lines of research.

 

To register and learn more about the event and the agenda, please visit: www.link.lunaphore.com/9pm

To learn more about Lunaphore, please visit: www.lunaphore.com

 

Disclaimer:

¹ The participation in the event is the sole decision of the speakers. The presentations are based on their personal experience and do not imply any official endorsement by their institutions.

 

 

 

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology that can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. Lunaphore recently completed registration as C corporation in the United States as part of its continuing global expansion to serve customers and partners in the translational and clinical research markets. For further information on Lunaphore and its products, please visit www.lunaphore.com.

 

For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]